Abiomed, Inc.

No quarterly operating results were reported on this call because it was an acquisition announcement rather than an earnings release. J&J said it will pay Abiomed shareholders $380 per share in cash upfront plus a non-tradable CVR worth up to $35 per share. Joe Wolk said the deal will be funded with cash on hand and short-term financing, and that it is expected to be slightly dilutive to neutral to adjusted EPS in the first year, about $0.05 accretive in 2024, and increasingly accretive thereafter. The company expects the transaction to close before the end of the first quarter of 2023, subject to tender and regulatory approvals.

Joaquin Duato framed the transaction as fully consistent with J&J’s strategy of focusing on pharmaceuticals and MedTech and improving MedTech execution. He said Abiomed strengthens J&J in a fast-growing cardiovascular category and helps bring new life-saving technologies to more patients worldwide. His tone was confident and strategic, with repeated emphasis on patient-first values, cultural fit, and long-term growth.

Joe Wolk described Abiomed as a scaled asset in large, underpenetrated markets with attractive long-term growth potential. He said J&J expects to fund the acquisition with cash on hand and short-term financing, while keeping capital allocation priorities unchanged: a superior credit profile, strong free cash flow, investment in R&D, selective M&A, and shareholder returns through dividends and buybacks when appropriate. He also said cost synergies should be modest, and that the financial case is driven more by growth than by cost takeout.

Analysts focused on why Abiomed was the chosen cardiology asset, whether the process was competitive, and why J&J used a CVR. Management said the deal fits J&J’s plan to expand into high-growth medtech and that the CVR was designed to give both sides upside if clinical and revenue milestones are achieved. On growth, management said the key drivers are international expansion, leveraging J&J’s commercial and regulatory infrastructure, and supporting ongoing trials such as RECOVER 4, PROTECT, and STEMI-related studies.